Exscientia PLC
NASDAQ:EXAI

Watchlist Manager
Exscientia PLC Logo
Exscientia PLC
NASDAQ:EXAI
Watchlist
Price: 4.84 USD Market Closed
Market Cap: 633.2m USD
Have any thoughts about
Exscientia PLC?
Write Note

Exscientia PLC
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Exscientia PLC
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Exscientia PLC
NASDAQ:EXAI
Income from Continuing Operations
-ÂŁ146m
CAGR 3-Years
-72%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Income from Continuing Operations
-$151.1m
CAGR 3-Years
-142%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Income from Continuing Operations
-$208.4m
CAGR 3-Years
-14%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Income from Continuing Operations
-$166.3m
CAGR 3-Years
-36%
CAGR 5-Years
-37%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Income from Continuing Operations
-ÂŁ55.3m
CAGR 3-Years
9%
CAGR 5-Years
5%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Income from Continuing Operations
ÂŁ2.4m
CAGR 3-Years
-63%
CAGR 5-Years
-19%
CAGR 10-Years
-22%
No Stocks Found

Exscientia PLC
Glance View

Market Cap
608.4m USD
Industry
Biotechnology

Exscientia Plc operates as an AI-driven pharmatech company which is engaged in designing and developing patient-based drugs. The company is headquartered in Oxford, Oxfordshire and currently employs 208 full-time employees. The company went IPO on 2021-10-01. The firm's focus is on the discovery, design and development of small molecule drug candidates. The firm has built a complete end-to-end solution of artificial intelligence (AI), and experimental technologies for target identification, drug candidate design, translational models and patient selection. Its AI process is comprised of the four elements: Precision Target, Precision Design, Precision Experiment and Precision Medicine. Its AI-design includes a range of deep learning and machine learning algorithms, generative methods, active learning and natural language processing. These methods are used to guide target selection, to design the precise molecular architecture of potential drug molecules and to analyze patient tissues to prioritize the molecules. The firm's lead drug candidate, EXS21546, is in early stage of development.

EXAI Intrinsic Value
4.74 USD
Overvaluation 2%
Intrinsic Value
Price

See Also

What is Exscientia PLC's Income from Continuing Operations?
Income from Continuing Operations
-146m GBP

Based on the financial report for Dec 31, 2023, Exscientia PLC's Income from Continuing Operations amounts to -146m GBP.

What is Exscientia PLC's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 3Y
-72%

Over the last year, the Income from Continuing Operations growth was 0%. The average annual Income from Continuing Operations growth rates for Exscientia PLC have been -72% over the past three years .

Back to Top